Alkem and Sonnet BioTherapeutics Team Up for Diabetic Neuropathy Treatment

Alkem Laboratories Ltd has partnered with Sonnet BioTherapeutics to develop and commercialize 'SON-080', a drug candidate for diabetic peripheral neuropathy, in India. Alkem will conduct clinical development and handle regulatory filings, holding exclusive rights in India. The partnership aims to address the large prevalence of this condition in the country.

Alkem Laboratories Ltd has announced a significant licensing agreement with U.S.-based company, Sonnet BioTherapeutics Holdings, Inc. The collaboration focuses on the development, manufacturing, and commercialization of a groundbreaking drug candidate, 'SON-080', specifically targeting diabetic peripheral neuropathy, within the Indian market.

Under this agreement, Alkem will spearhead the clinical development of 'SON-080' in India with dedicated support from Sonnet. The process involves managing both global and Indian regulatory filings; Alkem retains exclusive rights to develop, manufacture, and market the drug in India.

Akhilesh Sharma, President and Chief Medical Officer at Alkem, expressed optimism about the potential of 'SON-080', citing promising outcomes from translational studies in nerve regeneration. Sonnet's Founder and CEO, Pankaj Mohan, emphasized Alkem's expertise as a key factor in advancing the drug into phase 2 clinical trials through this strategic partnership.

(With inputs from agencies.)